Atara Biotherapeutics Receives Reissued Buy Rating from HC Wainwright as Investors Monitor Potential Growth Opportunities
Atara Biotherapeutics (NASDAQ:ATRA), a biotechnology company, recently received a reissued "buy" rating from HC Wainwright, according to a research note ...